Folic acid mitigates angiotensin-II-induced blood pressure and renal remodeling

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Pushpakumar, Sathnur B ^a   Kundu, Sourav ^a   Metreveli, Naira ^a   Sen, Utpal ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANGIOTENSIN II; CYSTATHIONINE BETA SYNTHASE; CYSTATHIONINE GAMMA LYASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOLIC ACID; GELATINASE A; GELATINASE B; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SUPEROXIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FLUID INTAKE; FOOD INTAKE; HOMEOSTASIS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INFLAMMATION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PARENCHYMA; METHYLATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RENAL REMODELING; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II; ANIMALS; ARGININE; BLOOD PRESSURE; COLLAGEN; DRINKING; FOLIC ACID; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84891300191     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083813     Document Type: Article

References (76)

1. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C (1997) High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 96: 1745-1749. (Pubitemid 27400728)
2. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, et al. (1999) Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney International 55: 1028-1035. (Pubitemid 29100715)
3. Hayden MR, Tyagi SC (2004) Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation. Nutr J 3: 4.
4. Sen U, Basu P, Abe OA, Givvimani S, Tyagi N, et al. (2009) Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. Am J Physiol Renal Physiol 297: F410-419.
5. Sen U, Munjal C, Qipshidze N, Abe O, Gargoum R, et al. (2010) Hydrogen sulfide regulates homocysteine-mediated glomerulosclerosis. Am J Nephrol 31: 442-455.
6. Boini KM, Xia M, Abais JM, Xu M, Li CX, et al. (2012) Acid sphingomyelinase gene knockout ameliorates hyperhomocysteinemic glomerular injury in mice lacking cystathionine-beta-synthase. PLoS One 7: e45020.
7. Yi F, Xia M, Li N, Zhang C, Tang L, et al. (2009) Contribution of guanine nucleotide exchange factor Vav2 to hyperhomocysteinemic glomerulosclerosis in rats. Hypertension 53: 90-96.
8. Yi F, Zhang AY, Li N, Muh RW, Fillet M, et al. (2006) Inhibition of ceramideredox signaling pathway blocks glomerular injury in hyperhomocysteinemic rats. Kidney International 70: 88-96. (Pubitemid 44000124)
9. Tummalapalli CM, Tyagi SC (1999) Responses of vascular smooth muscle cell to extracellular matrix degradation. J Cell Biochem 75: 515-527. (Pubitemid 29521658)
10. Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69: 562-573. (Pubitemid 43139720)
11. AK A (2009) Matrix Metalloproteinases and Their Inhibitors in Kidney Scarring: Culprits or Innocents. Journal of Health Science 55: 473-483.
12. Melendez-Zajgla J, Del Pozo L, Ceballos G, Maldonado V (2008) Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol Cancer 7: 85.
13. Sen U, Rodriguez WE, Tyagi N, Kumar M, Kundu S, et al. (2008) Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance. Am J Physiol Endocrinol Metab 295: E1205-1212.
14. Chirco R, Liu XW, Jung KK, Kim HR (2006) Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25: 99-113. (Pubitemid 43723986)
15. Solini A, Santini E, Nannipieri M, Ferrannini E (2006) High glucose and homocysteine synergistically affect the metalloproteinases-tissue inhibitors of metalloproteinases pattern, but not TGFB expression, in human fibroblasts. Diabetologia 49: 2499-2506. (Pubitemid 44362506)
16. Yang ZZ, Zou AP (2003) Homocysteine enhances TIMP-1 expression and cell proliferation associated with NADH oxidase in rat mesangial cells. Kidney International 63: 1012-1020.
17. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676. (Pubitemid 36749215)
18. Chang PY, Lu SC, Lee CM, Chen YJ, Dugan TA, et al. (2008) Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast growth factor-2 involving G protein and DNA methylation. Circ Res 102: 933-941. (Pubitemid 351591555)
19. Loscalzo J (2009) Homocysteine-mediated thrombosis and angiostasis in vascular pathobiology. J Clin Invest 119: 3203-3205.
20. Sodha NR, Clements RT, Boodhwani M, Xu SH, Laham RJ, et al. (2009) Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Am J Physiol Heart Circ Physiol 296: H428-434.
21. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, et al. (2002) The antitumoral effect of endostatin and angiostatin is associated with a downregulation of vascular endothelial growth factor expression in tumor cells. FASEB J 16: 1802-1804.
22. Granger JP (2009) Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors? Hypertension 54: 465-467.
23. Advani A, Kelly DJ, Advani SL, Cox AJ, Thai K, et al. (2007) Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A 104: 14448-14453. (Pubitemid 350003281)
24. Stopper H, Treutlein AT, Bahner U, Schupp N, Schmid U, et al. (2008) Reduction of the genomic damage level in haemodialysis patients by folic acid and vitamin B12 supplementation. Nephrol Dial Transplant 23: 3272-3279.
25. Clarke ZL, Moat SJ, Miller AL, Randall MD, Lewis MJ, et al. (2006) Differential effects of low and high dose folic acid on endothelial dysfunction in a murine model of mild hyperhomocysteinaemia. Eur J Pharmacol 551: 92-97. (Pubitemid 44648062)
26. Wentzel P, Gareskog M, Eriksson UJ (2005) Folic acid supplementation diminishes diabetes- and glucose-induced dysmorphogenesis in rat embryos in vivo and in vitro. Diabetes 54: 546-553.
27. Qipshidze N, Tyagi N, Metreveli N, Lominadze D, Tyagi SC (2012) Autophagy mechanism of right ventricular remodeling in murine model of pulmonary artery constriction. Am J Physiol Heart Circ Physiol 302: H688-696.
28. Sen U, Tyagi N, Kumar M, Moshal KS, Rodriguez WE, et al. (2007) Cystathionine-beta-synthase gene transfer and 3-deazaadenosine ameliorate inflammatory response in endothelial cells. Am J Physiol Cell Physiol 293: C1779-1787. (Pubitemid 350255073)
29. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, et al. (2001) Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104: 2569-2575. (Pubitemid 33104795)
30. Lim U, Cassano PA (2002) Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 156: 1105-1113. (Pubitemid 35453681)
31. Kahleova R, Palyzova D, Zvara K, Zvarova J, Hrach K, et al. (2002) Essential hypertension in adolescents: association with insulin resistance and with metabolism of homocysteine and vitamins. Am J Hypertens 15: 857-864. (Pubitemid 35168424)
32. Pousse H, Ayachi R, Essoussi AS, el May A, el Amri H (1990) [2 familial cases of homocystinuria one of which revealed by fatal hypertensive encephalopathy]. Ann Pediatr (Paris) 37: 189-192. (Pubitemid 20138244)
33. Cichocka E, Kubalska J (1995) [Arterial hypertension as a complication of homocystinuria in a 14-year old boy]. Pediatr Pol 70: 171-176.
34. Papandreou D, Malindretos P, Arvanitidou M, Makedou A, Rousso I (2010) Homocysteine lowering with folic acid supplements in children: effects on blood pressure. Int J Food Sci Nutr 61: 11-17.
35. Kennedy BP, Farag NH, Ziegler MG, Mills PJ (2003) Relationship of systolic blood pressure with plasma homocysteine: importance of smoking status. J Hypertens 21: 1307-1312.
36. Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA (1995) Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology 6: 219-226.
37. Wang X, Qin X, Demirtas H, Li J, Mao G, et al. (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369: 1876-1882. (Pubitemid 46829358)
38. Ericson U, Sonestedt E, Gullberg B, Olsson H, Wirfalt E (2007) High folate intake is associated with lower breast cancer incidence in postmenopausal women in the Malmo Diet and Cancer cohort. Am J Clin Nutr 86: 434-443. (Pubitemid 47256929)
39. Persson EC, Schwartz LM, Park Y, Trabert B, Hollenbeck AR, et al. (2013) Alcohol consumption, folate intake, hepatocellular carcinoma, and liver disease mortality. Cancer Epidemiol Biomarkers Prev 22: 415-421.
40. Christen WG, Glynn RJ, Chew EY, Albert CM, Manson JE (2009) Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med 169: 335-341.
41. Title LM, Cummings PM, Giddens K, Genest JJ, Jr., Nassar BA (2000) Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 36: 758-765.
42. Doshi SN, McDowell IF, Moat SJ, Lang D, Newcombe RG, et al. (2001) Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol 21: 1196-1202. (Pubitemid 34215150)
43. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Newcombe RG, et al. (1999) Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. Eur J Clin Invest 29: 659-662. (Pubitemid 29366712)
44. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, et al. (1999) Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 34: 2002-2006. (Pubitemid 30002657)
45. Verhaar MC, Wever RM, Kastelein JJ, van Loon D, Milstien S, et al. (1999) Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial. Circulation 100: 335-338. (Pubitemid 29362401)
46. Wilmink HW, Stroes ES, Erkelens WD, Gerritsen WB, Wever R, et al. (2000) Influence of folic acid on postprandial endothelial dysfunction. Arterioscler Thromb Vasc Biol 20: 185-188. (Pubitemid 30048362)
47. Nakano E, Higgins JA, Powers HJ (2001) Folate protects against oxidative modification of human LDL. Br J Nutr 86: 637-639. (Pubitemid 34051424)
48. Moens AL, Champion HC, Claeys MJ, Tavazzi B, Kaminski PM, et al. (2008) High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation 117: 1810-1819. (Pubitemid 351507469)
49. Xun P, Liu K, Loria CM, Bujnowski D, Shikany JM, et al. (2012) Folate intake and incidence of hypertension among American young adults: a 20-y follow-up study. Am J Clin Nutr 95: 1023-1030.
50. Arendshorst WJ, Brannstrom K, Ruan X (1999) Actions of angiotensin II on the renal microvasculature. J Am Soc Nephrol 10 Suppl 11: S149-161. (Pubitemid 29038180)
51. Chen L, Miao Y, Zhang Y, Dou D, Liu L, et al. (2012) Inactivation of the Eprostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility. Arterioscler Thromb Vasc Biol 32: 3024-3032.
52. Harding P, Yang XP, He Q, Lapointe MC (2011) Lack of microsomal prostaglandin E synthase-1 reduces cardiac function following angiotensin II infusion. Am J Physiol Heart Circ Physiol 300: H1053-1061.
53. Feng W, Chumley P, Hua P, Rezonzew G, Jaimes D, et al. (2012) Role of the transcription factor erythroblastosis virus E26 oncogen homolog-1 (ETS-1) as mediator of the renal proinflammatory and profibrotic effects of angiotensin II. Hypertension 60: 1226-1233.
54. Soler MJ, Wysocki J, Ye M, Lloveras J, Kanwar Y, et al. (2007) ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney International 72: 614-623. (Pubitemid 47312795)
55. Sen U, Tyagi SC (2010) Homocysteine and Hypertension in Diabetes: Does PPARgamma Have a Regulatory Role? PPAR Res 2010: 806538.
56. Fiedler L (2008) The DDAH/ADMA pathway is a critical regulator of NO signalling in vascular homeostasis. Cell Adh Migr 2: 149-150.
57. Holven KB, Haugstad TS, Holm T, Aukrust P, Ose L, et al. (2003) Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects. Br J Nutr 89: 359-363. (Pubitemid 36422777)
58. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G (2003) Implications of oxidative stress and homocysteine in the pathophysiology of essential hypertension. J Cardiovasc Pharmacol 42: 453-461. (Pubitemid 37210858)
59. Horvath B, Mukhopadhyay P, Kechrid M, Patel V, Tanchian G, et al. (2012) beta-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner. Free Radic Biol Med 52: 1325-1333.
60. Soetikno V, Sari FR, Lakshmanan AP, Arumugam S, Harima M, et al. (2012) Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2-keap1 pathway. Mol Nutr Food Res.
61. Petry A, Djordjevic T, Weitnauer M, Kietzmann T, Hess J, et al. (2006) NOX2 and NOX4 mediate proliferative response in endothelial cells. Antioxid Redox Signal 8: 1473-1484. (Pubitemid 44726324)
62. Joseph J, Joseph L, Devi S, Kennedy RH (2008) Effect of anti-oxidant treatment on hyperhomocysteinemia-induced myocardial fibrosis and diastolic dysfunction. J Heart Lung Transplant 27: 1237-1241.
63. Tyagi N, Qipshidze N, Sen U, Rodriguez W, Ovechkin A, et al. (2011) Cystathionine beta synthase gene dose dependent vascular remodeling in murine model of hyperhomocysteinemia. Int J Physiol Pathophysiol Pharmacol 3: 210-222.
64. Sen U, Moshal KS, Tyagi N, Kartha GK, Tyagi SC (2006) Homocysteineinduced myofibroblast differentiation in mouse aortic endothelial cells. J Cell Physiol 209: 767-774. (Pubitemid 44665699)
65. Kumagai H, Katoh S, Hirosawa K, Kimura M, Hishida A, et al. (2002) Renal tubulointerstitial injury in weanling rats with hyperhomocysteinemia. Kidney International 62: 1219-1228.
66. Zhu XY, Urbieta Caceres VH, Favreau FD, Krier JD, Lerman A, et al. (2011) Enhanced endothelial progenitor cell angiogenic potency, present in early experimental renovascular hypertension, deteriorates with disease duration. J Hypertens 29: 1972-1979.
67. Taimeh Z, Loughran J, Birks EJ, Bolli R (2013) Vascular endothelial growth factor in heart failure. Nat Rev Cardiol 10: 519-530.
68. Tanaka T, Nangaku M (2013) Angiogenesis and hypoxia in the kidney. Nat Rev Nephrol 9: 211-222.
69. Kitayama H, Maeshima Y, Takazawa Y, Yamamoto Y, Wu Y, et al. (2006) Regulation of angiogenic factors in angiotensin II infusion model in association with tubulointerstitial injuries. Am J Hypertens 19: 718-727. (Pubitemid 43928512)
70. Sen U, Herrmann M, Herrmann W, Tyagi SC (2007) Synergism between AT1 receptor and hyperhomocysteinemia during vascular remodeling. Clin Chem Lab Med 45: 1771-1776. (Pubitemid 350232979)
71. Neves MF, Endemann D, Amiri F, Virdis A, Pu Q, et al. (2004) Small artery mechanics in hyperhomocysteinemic mice: effects of angiotensin II. J Hypertens 22: 959-966. (Pubitemid 38680471)
72. Virdis A, Iglarz M, Neves MF, Amiri F, Touyz RM, et al. (2003) Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice. Arterioscler Thromb Vasc Biol 23: 1352-1357. (Pubitemid 36994521)
73. McLennan SV, Kelly DJ, Cox AJ, Cao Z, Lyons JG, et al. (2002) Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 45: 268-275. (Pubitemid 34208390)
74. McNulty M, Mahmud A, Spiers P, Feely J (2006) Collagen type-I degradation is related to arterial stiffness in hypertensive and normotensive subjects. J Hum Hypertens 20: 867-873. (Pubitemid 44614069)
75. Geisel J, Zimbelmann I, Schorr H, Knapp JP, Bodis M, et al. (2001) Genetic defects as important factors for moderate hyperhomocysteinemia. Clin Chem Lab Med 39: 698-704. (Pubitemid 32894413)
76. Varga EA, Sturm AC, Misita CP, Moll S (2005) Cardiology patient pages. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease. Circulation 111: e289-293.